{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(44)"],"submitter":["Bocchia M"],"pubmed_abstract":["Several reports described an increased risk of cardiovascular (CV) events, mainly atherothrombotic, in Chronic Myeloid Leukemia (CML) patients receiving nilotinib. However, the underlying mechanism remains elusive. The objective of the current cross-sectional retrospective study is to address a potential correlation between Tyrosine Kinase Inhibitors (TKIs) treatment and CV events. One hundred and 10 chronic phase CML patients in complete cytogenetic response during nilotinib or imatinib, were screened for CV events and evaluated for: traditional CV risk factors, pro/anti-inflammatory biochemical parameters and detrimental ORL1 gene polymorphisms (encoding for altered oxidized LDL receptor-1). Multivariate analysis of the whole cohort showed that the cluster of co-existing nilotinib treatm"],"journal":["Oncotarget"],"pagination":["72311-72321"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5342164"],"repository":["biostudies-literature"],"pubmed_title":["Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients."],"pmcid":["PMC5342164"],"pubmed_authors":["Aprile L","Gozzini A","Sicuranza A","Abruzzese E","Gozzetti A","Bocchia M","Defina M","Trawinska MM","Fontanelli G","Petrini M","Galimberti S","Bosi A","Santilli F","Scappini B","Puccetti L","Barate C"],"additional_accession":[]},"is_claimable":false,"name":"Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.","description":"Several reports described an increased risk of cardiovascular (CV) events, mainly atherothrombotic, in Chronic Myeloid Leukemia (CML) patients receiving nilotinib. However, the underlying mechanism remains elusive. The objective of the current cross-sectional retrospective study is to address a potential correlation between Tyrosine Kinase Inhibitors (TKIs) treatment and CV events. One hundred and 10 chronic phase CML patients in complete cytogenetic response during nilotinib or imatinib, were screened for CV events and evaluated for: traditional CV risk factors, pro/anti-inflammatory biochemical parameters and detrimental ORL1 gene polymorphisms (encoding for altered oxidized LDL receptor-1). Multivariate analysis of the whole cohort showed that the cluster of co-existing nilotinib treatm","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Nov","modification":"2026-05-30T05:42:52.222Z","creation":"2019-03-27T02:38:09Z"},"accession":"S-EPMC5342164","cross_references":{"pubmed":["27527867"],"doi":["10.18632/oncotarget.11100"]}}